Trial evaluates Olaparib combinations for effectiveness in DNA repair defects, highlighting challenges in treatment.
The study failed to meet its primary end point of ORR. DDR and homologous recombination repair defects are not consistently actionable with olaparib as monotherapy or in combination with other targeted therapies in a histology-agnostic manner.
No takes yet. Share an insight, caveat, or question.
Doroshow et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: